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Abstract
Background: The two largest needle exchange programs (NEPs) in Hungary were forced to close down in the second
half of 2014 due to extreme political attacks and related lack of government funding. The closures occurred against a
background of rapid expansion in Hungary of injectable new psychoactive substances, which are associated with very
frequent injecting episodes and syringe sharing. The aim of our analysis was to predict how the overall Hungarian NEP
syringe supply was affected by the closures.
Methods: We analyzed all registry data from all NEPs in Hungary for all years of standardized NEP data collection
protocols currently in use (2008–2014) concerning 22 949 client enrollments, 9 211 new clients, 228 167 client
contacts, 3 160 560 distributed syringes, and 2 077 676 collected syringes.
Results: We found that while the combined share of the two now closed NEPs decreased over time, even in their
partial year 2014 they still distributed and collected about half of all syringes, and attended to over half of all clients
and client contacts in Hungary. The number of distributed syringes per PWID (WHO minimum target = 100) was 81 in
2014 in Hungary, but 39 without the two now closed NEPs.
Conclusions: There is a high probability that the combination of decreased NEP coverage and the increased injection
risk of new psychoactive substances may lead in Hungary to a public health disaster similar to the HIV outbreaks in
Romania and Greece. This can be avoided only by an immediate change in the attitude of the Hungarian government
towards harm reduction.
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Background
Injecting drug use is a major risk factor in the transmission
of HIV and Hepatitis C virus (HCV) [1, 2]. There is sub-
stantial evidence to support the effectiveness of harm re-
duction interventions such as needle exchange programs
(NEP) in reducing HIV and HCV transmission among
people who inject drugs (PWIDs) [2–7], although the link
between HCV transmission and NEP alone is unclear [3,
7]. A large body of research has emphasized the importance
of complex interventions, such as the integration of NEPs,
drug treatment, anti-viral treatment and other harm reduc-
tion interventions as effective strategies in combating the
HIV and HCV epidemic among PWIDs [5, 6, 8–10].
Therefore, we can conclude that NEPs are key elements of
effective HIV and HCV prevention strategies [11], even re-
gardless of the income level of the country where they are
located (high income vs. middle income vs. low income
countries), indicating that it is the effectiveness of NEPs to
reach PWIDs – also referred to as “coverage” – rather than
the economic background per se that really matters [12].
In their publication updated in 2012 [13], the World
Health Organization (WHO) underlines the importance of
NEPs, among other sources of sterile needles and syringes,
not only in their role of preventing drug related infectious
diseases, but also as important contacts with and potential
entry points to health services. The number of distrib-
uted syringes per PWID per year is a WHO indicator
(reference number: NSP.C.1c) to measure NEP cover-
age [13]. WHO sets the minimum target in this indi-
cator at 100 (low coverage) and the desirable target
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at 200 (high coverage) for HIV prevention, noting
that levels required for HCV prevention are likely to
be much higher than these values [13].
After HIV was discovered in 1981 as the cause of AIDS,
guidelines and recommendations were developed to curb
the HIV epidemic among PWIDs as well [14]. However,
HIV is still very prevalent in many PWID populations
around the world [15]. One reason for this is the limited
resources available in certain countries for harm reduction
among PWIDs, but probably the main reason is a lack of
supporting policies or political will linked to the
stigmatization of drug users and drug use [14]: while
higher income countries have more developed and better
implemented harm reduction programs (including NEPs)
among PWIDs, this is not the case in much of the middle
or low income countries. For example, the sustained ex-
tremely low HIV transmission rates among PWIDs in
Australia have been attributed to early and sustained harm
reduction responses (such as NEPs) backed by strong drug
policy and political support [16]. On the other hand, the
United States has the lowest level of NEP availability in
the developed world [17], which probably has a lot to do
with a federal ban on funding NEPs [18].
The first NEP in Hungary opened in 1994 under the
auspices of the Drug Prevention Foundation (DPA),
using a loophole in Hungarian legislation. In the early
2000s, NEPs already played an important role: 40 % of
street recruited PWIDs reported that they obtained all
their syringes from the NEP [19], and the Hungarian
National Focal Point (HNFP) estimated that about 49 %
of PWIDs were reached by NEP services [20]. By the
end of 2014, there were 31 NEPs in the country – the
largest (in terms of number of clients, contact, and
syringes distributed) being Blue Point and the second
largest being DPA. At this point, there is still a lack of
either legal restriction or legal permission of needle ex-
change operations in Hungary. However, DPA and Blue
Point NEPs closed in Budapest at the end of 2014 due to
political attacks and a related considerable reduction in
government funding for harm reduction activities and
programs [21]. Much of these political attacks had to do
with blames against the NEPs of “distributing syringes”
instead of “exchanging syringes”, due to their so-called
“one-for-one plus” exchange policy, where NEPs ex-
change syringes but also give additional syringes in
addition to the number that was exchanged [22], and
with the gentrification of the districts where these needle
exchanges were operating. A corroborating body of re-
search, however, shows that actually “distributing syrin-
ges” (meaning: giving out the amount of syringes based
upon need as opposed to how many syringes were
turned in by the clients) was associated with lower odds
of syringe re-use – although not with receptive or dis-
tributive syringe sharing – when compared to “one-for-
one” or “one-for-one plus” syringe exchange policies
[22–25]. In addition, increased access to sterile syringes –
not surprisingly – lead to a decrease in both distributive
and receptive syringe sharing, and consequently to declin-
ing HIV incidence in a prospective cohort study among
over a thousand PWIDs in Vancouver, Canada [26].
Given that these were the two largest NEPs not only
in Budapest, but also in Hungary, the closures may have
a largely detrimental effect on harm reduction efforts in
the country. The goal of this analysis was to predict how
the overall Hungarian NEP syringe supply was affected
by the closures, by calculating the combined share of
Blue Pont and Drug Prevention Foundation (DPA) NEPs
across five turnover data types using all turnover data
from all NEPs in Hungary during the years between
2008 and 2014, and by calculating how the number of
distributed syringes per PWID per year decreased as a
result of the closures.
Methods
Data sources
Collection of standardized NEP registry data (also referred
to as “NEP client turnover data”) started in 2003 in
Hungary. In 2008 the protocol was slightly changed to in-
clude data for new clients as well. In this study, we analyze
all client turnover data for altogether 22 949 client enroll-
ments, 9 211 new clients, 228 167 client contacts, 3 160
560 distributed syringes, and 2 077 676 collected syringes
from all NEPs in Hungary between 2008 and 2014, that is,
for all years of standardized NEP data collection protocols
that are currently in use, until the year when Blue Point
and DPA were closed (year 2014). Since Blue Point NEP
was closed down in August 2014 and DPA was closed
down in November of 2014, they contributed only seven
and ten full months, respectively, to year 2014, while all
other NEPs contributed 12 months of data. During this
period, the number of NEPs gradually increased from 18
in 2008 to 31 at the end of 2014.
As part of routine data collection, Hungarian NEPs
record and then aggregate at the end of each year five
types of turnover data: number of clients, number of
new clients, number of client contacts, number of dis-
tributed syringes, and number of collected syringes. The
“number of clients” variable refers to client enrollments,
meaning it is the number of unique clients who had at
least one visit at a given NEP during a given year.
Double entries for the same client are deleted at the
level of service providers, but not at national level. The
“number of new clients” variable – a subset of the “num-
ber of clients” variable – denotes the number of individ-
uals during a given year who register for the first time
into the database of a particular NEP. One client contact
means one visit by a client in the NEP; therefore, the
“number of client contacts” variable describes all visits
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by all clients at a particular needle exchange during a given
year. The “number of distributed syringes” is the number of
all syringes handed out to clients by a given NEP in a given
year. The “number of collected syringes” is the sum of the
number of used syringes that were returned by clients to
the NEP and the number of syringes that were collected by
NEP staff (e.g. on the streets or in parks).
All Hungarian NEPs are obliged to report their respect-
ive aggregate client turnover data to the HNFP, who is
then obliged to report a summary of the aggregate data to
the European Monitoring Centre for Drugs and Drug Ad-
diction (EMCDDA) in form of a national report. The
HNFP usually releases the official NEP data in the middle
of the year for the previous year (e.g. data were released
on 24 June 2015 for the year 2014). For this analysis, we
used a combination of individual aggregate NEP data and
aggregate summary NEP data, as follows: annual aggregate
data referring to Blue Point NEP and the NEP operated by
DPA were provided directly to the authors by the respect-
ive NEPs. Annual aggregate summary data concerning all
other NEPs in Hungary, stratified by two geographical
locations (in Budapest vs. outside of Budapest), were
provided by the HNFP. The collection of primary data
that constitutes the basis for this secondary analysis was
ethically approved by the Supervisory Boards of the re-
spective NEPs.
Data management and analysis
We calculated the following two indicators for each year:
1. the combined share of the two needle exchange pro-
grams operated by Blue Point and DPA (this indicator
was calculated for all five turnover data types), 2. the
number of distributed syringes per PWID per year.
The combined share of the two needle exchange pro-
grams operated by Blue Point and DPA was calculated,
for each five turnover data types, as: (the total number of
[turnover data type] for Blue Point + the total number of
[turnover data type] for DPA) / the total number of
[turnover data type] for all NEPs in Hungary.
The original equation to calculate the number of distrib-
uted syringes per PWID per year [13] also includes the
number of syringes sold to PWID in pharmacies and other
outlets. Pharmacy sales data, however, are not recorded in
Hungary – similarly to most countries [13]. Therefore, we
calculated this indicator as: the total number of syringes
distributed by all NEPs in Hungary in a given year / the
estimated number of PWIDs in Hungary. The only avail-
able estimation of the size of the PWID population in
Hungary was calculated in 2010 [27] using the capture-
recapture method, and it set the figure at 5 699 persons.
Results
During the seven years of the study, the number of both
all and new clients, and the number of client contacts
showed an overall increase in Hungary (Fig 1a, b and c).
By contrast, the number of distributed and collected sy-
ringes increased until 2011, then in 2012 dropped
sharply and stayed at about the same level for three
years (Fig. 1d and e). About 90 % of all client indicators
were recorded in Budapest and about 10 % outside of
the city.
Blue Point's and DPA’s combined share of distributed
and collected syringes, and number of both all and new
clients declined over time, but their combined share of
client contacts showed an increasing trend (Fig. 2). In
their last full year of operation, in 2013, Blue Point and
DPA together distributed and collected about half of all
syringes, and attended to about two thirds of all clients
and client contacts in Hungary. In the year of their clos-
ure, in 2014, their share was about half for all client indi-
cators. The number of distributed syringes per PWID
per year increased constantly until 2011 (where it peaked
at 114), then by 2012 it decreased sharply and stayed at
a level of about 80 for three years (81 in 2014) – when
the NEPs operated by Blue Point and DPA are excluded,
this number drops to 39 in 2014 (Fig. 3).
Discussion
The two largest NEPs in Hungary were forced to close
down after the second third of 2014 due to extreme pol-
itical pressure and related lack of government funding.
The aim of our analysis was to assess how the overall
Hungarian NEP syringe supply was affected by the clo-
sures, by assessing all turnover data from all NEPs in
Hungary between 2008 and 2014. First, we would like to
explain and put into context our findings, and then elab-
orate on the context and what the closure of these NEPs
means not only for the functioning of the Hungarian
harm reduction services but also for the epidemiological
situation of the country.
There was an increase in all turnover data between
2008 and 2011, for which there are several reasons. First,
an increase in the number of both clients and contacts,
and distributed and returned syringes may be the reflec-
tion of an increase in the access of PWIDs to NEPs due
to an increase in NEP awareness and/or reduction in the
stigma associated with accessing harm reduction ser-
vices. Second, it may reflect an increasing demand for
injecting equipment linked to the increasing prevalence
of use of injectable new psychoactive substances (NPS),
especially cathinones, which are associated with higher
injecting frequencies than “traditional” drugs, such as
heroin or amphetamine [28].
After the Fidesz - Hungarian Civic Alliance entered
into power in 2010 [29], there was an immediate attack
on Hungary’s drug policy and all harm reduction activ-
ities [21]. This resulted in a drastic cut in 2011 in needle
exchange funding for the year 2012 and thereafter. The
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Fig. 1 Client turnover data for all clients in all NEPs in Hungary between 2008 and 2014, by NEP (Note: NEPs in Budapest other than Blue Point
and DPA are aggregated as one group, and NEPs outside of Budapest are aggregated as one group). a Number of all clients. b Number of new
clients. c Number of client contacts. d Number of number of distributed syringes. e Number of number of collected syringes.
Fig. 2 Blue Point and DPA NEPs’ combined share of all clients, new clients, client contacts, distributed syringes, and collected syringes of all
clients and all NEPs in Hungary between 2008 and 2014
Gyarmathy et al. BMC Public Health  (2016) 16:157 Page 4 of 7
cuts in funding are reflected in our data: the number of
both distributed and collected syringes plummeted in
2012, while the number of all and new clients, and client
contact kept increasing, indicating the presence of de-
mand for injecting equipment.
While by 2011 Hungary slightly exceeded the minimal
WHO target of 100, between 2012 and 2014 the indica-
tor fell back to a pre-2010 level of about 80 (about two
thirds of what it was a year before). Moreover, when the
two now closed largest NEPs are excluded, the indicator
vacillates in the miserly thirties after 2011. Since there is
no indication whatsoever that any of Blue Point and
DPA NEP funding will be redistributed to other NEPs in
Budapest or Hungary, or that there will be an increase
in NEP funding for the NEPs that are still open, we
expect the number of syringes distributed per PWID per
year in Hungary to stay in the low thirties in the upcom-
ing years as well. In addition, some populations, such as
the segregated, low SES and mainly Roma populations
that Blue Point NEP was serving, will be largely un-
served [21]. Therefore, the NEP coverage in Hungary
will not be sufficient to effectively prevent an HIV
epidemic.
Due to a considerable decrease in funding, NEPs had
to institute caps on distributed syringes: for example,
until May 2012, clients at Blue Point were allowed to
exchange an unlimited number of used needles,
whereas afterwards the maximum number of exchange-
able syringes was reduced to between 2 and 5 per client
per visit (depending on actual availability of funding).
Similar restrictions were instituted at DPA as early as
2011. Due to the restrictions, we estimate that fewer
of the distributed syringes were returned to the NEPs
and more of them stayed in circulation (most prob-
ably for reuse) after being used. As a matter of fact,
clients at Blue Point NEP reported to staff that they
kept the used syringes for later reuse, for as many as
6–8 times, due to a lack of access to sterile syringes.
The question arises: why don’t PWIDs just go to the
pharmacy to buy syringes? The answer is multifaceted,
but has one interesting element. PWIDs in Hungary
traditionally use one-piece diabetic syringes [30], which
up till the recent past were easily available in any
pharmacy. Due to the wide adoption of new technology,
however, about 90 % of diabetic patients in Europe (in
Hungary as well) use insulin pens instead of diabetic sy-
ringes [31]. This means that those syringes that PWIDs
use to inject drugs can be purchased only at selected
pharmacies and only in small quantities, and generally
only two-piece syringes are available now in pharmacies
(Gyarmathy, personal communication). Not only are
the needles of two-piece syringes wider and thereby
more uncomfortable to inject with (causing more vein
damage and epidermal infections), but their use has
also been found to be associated with a higher risk of
both HIV and HCV transmission [28, 32–34].
Some limitations are noteworthy. As we noted in the
methods, duplicate client data are deleted at the service
provider level, but not at national level. Therefore, some
clients may be registered with more than one NEP, and
thereby counted two or more times. Staff at Blue Point,
however, regularly walk around the city and pass by
other NEPs, and they reported very little overlap among
the clientele of different NEPs. Furthermore, the fact
that almost 90 % of Blue Point clients live in the 8th dis-
trict, which is the district where Blue Point is located,
and only 1 % live in the 13th district, which is the district
where DPA is located [35], suggests that the overwhelm-
ing majority of clients go to the NEP that is located close
to where they live and only a few percent may be double
counted by also visiting NEPs outside their living area.
Another limitation is that the increase in the number of
client contacts and all and new clients may be an arte-
fact due to a limit in the number of needles clients could
take as a result of limited funding: clients compensated
for the lower number of syringes they could take with
Fig. 3 The number of distributed syringes per PWID per year in Hungary between 2008 and 2014
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more frequent visits to the NEPs and more PWID had
to visit the NEPs as sending one’s used syringes with
someone else was not a viable option anymore (since
one client could exchange only a limited number of sy-
ringes). While some of the increase may be explained
with this, much of it is part of a trend: a continuation of
a decade long upward trend in client and contact num-
bers. Furthermore, we had only one estimate (from
2010) of the number of PWIDs in Hungary, and we used
this for all years to calculate the number of syringes per
PWID per year. The only available estimation does not
reflect the changes occurred during the recent years,
namely that due to the emergence of NPS – much of
which require injecting – there may have been an in-
crease in the number of PWIDs in Hungary. It is likely
that the actual population before 2010 could be some-
what smaller and after 2010 it could be somewhat larger
than the estimation we used; therefore, the number of
syringes per PWID per year indicator that we have cal-
culated may be somewhat imprecise and probably over-
estimated. Since no confidence limits were published
along with the estimate of PWIDs, we are unable to re-
port estimates of uncertainty for the number of syringes
distributed per person per year. In addition, since phar-
macy syringe distribution data are unavailable, coverage
estimates may be somewhat underestimated. With the
closure of the two largest NEPs in Hungary, about two
thirds of PWIDs who are NEP clients may now be un-
served or underserved, and it is likely that the number of
distributed sterile one-piece syringes will have decreased
to about half. As a result, the number of syringes distrib-
uted per PWID per year will probably fall to just over a
third of the minimum level recommended by WHO.
Given the fact that the latest data for this analysis are
from 2014, and data for the year 2015 are available only
in mid-2016, we were unable to assess the actual NEP
availability for the year 2015. During 2015, no qualitative
or quantitative studies in Hungary assessed the effect of
the 2014 NEP closures. A documentary film that was
produced in the middle of 2015, however, supports our
analysis findings [36]. While there is a new foundation
with a handful of people distributing syringes on the
street on certain days, their provision capacity is a negli-
gible fraction of what the now two closed NEPs pro-
vided. Drug users interviewed in this film complain
about the unavailability of syringes and that as a result
they are resorted to using one syringe for up to one
month, picking up used syringes from the street to
reuse, and to sharing the same syringe multiple times.
Another problem that drug users mentioned was the
lack support other than syringe provision and lack of
service access that were available at the NEPs that are
now closed. This, clearly, unerlines our findings and
points to a dramatic increase in injecting risk.
The changes that we describe in this analysis oc-
curred against a background of rapid expansion of NPS
(especially synthetic injectable cathinones), which are
associated with a higher number of injecting episodes, a
drastic increase in daily injecting, and an increase in
syringe sharing (resulting from a combination of more
injecting and fewer available sterile syringes) [21, 28],
and a reduction in the availability of one-piece diabetic
syringes in pharmacies due to the wide dissemination
of diabetic pens. To put this into context: the current
level in Hungary of the number of syringes distributed
per PWID per year is even below the levels that existed
in Romania before the HIV outbreak among PWIDs
started in 2011 (55 in Romania in 2010 vs. in the 30s in
Hungary now) [13]. In addition, a substantial increase
in drug injecting and syringe sharing took place both in
Greece and in Romania just a few years before the HIV
epidemic among PWIDs in 2011 and 2012.
Conclusions
There is a high probability that the combination of de-
creased access to sterile one-piece syringes (and the result-
ing move to injecting with two-piece syringes), and NPS
that are associated with considerably more frequent inject-
ing episodes may lead in Hungary to a public health disas-
ter similar to the HIV outbreaks in Romania and Greece.
As a matter of fact, between 2011 and 2014 (during the
time when the number of syringes per PWID per year
dropped from 114 to 39) the prevalence of HCV among
PWIDs in Hungary doubled (from 24 % to 49 % in the
country and from 34 % to 60 % in Budapest, respectively),
indicating that the epidemiological predisposition for a
drug injecting related infectious disease epidemic is
present - putting an end to an era of near-zero HIV preva-
lence among PWIDs [37]. This can be avoided only by a
change in the attitude of the Hungarian government to-
wards harm reduction and a related scaling up of NEP
services.
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